

ASX RELEASE

11th February 2021

Paradigm Appoints Helen Fisher as Non-Executive Director

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce the appointment of Helen Fisher to its Board as Non-Executive Director and Chair of the Audit and Risk Committee.

Paradigm continues to progress toward submission of the IND for Zilosul® and focus on implementation of the OA clinical program to support commercialisation. Effective 23rd of February 2021, Paradigm is delighted to welcome Helen to the Board. With a deep understanding of the health care sector, combined with her first-hand commercial experience and technical background in law, science and finance, Helen will bring the necessary skills and experience to the Paradigm Board for our future growth as we globalise the organisation.

Helen is CEO and managing director of Bio Capital Impact Fund (BCIF) and a Non-Executive Director (NED) and Chair of the Audit and Risk Committee of Calix Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech and pharmaceutical areas. Helen previously held a NED and Chair of the Audit and Risk Committee position at Sienna Cancer Diagnostics Limited before it was acquired by BARD1 (ASX:BD1).

Helen is currently the chair of the Victorian branch of AusBiotech.

Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte's life sciences practice in Australia for 5 years, having had many years' experience in the life sciences and health care sector. She also specialised in the financial services sector, servicing some of the largest global and Australian banks and funds, as well as having advised on a number of significant M&A transactions.

Helen has provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP and supply chain management.

Helen has bachelor's degrees in Law (with honours) and Science from the University of Melbourne, a master's degree in laws (specialising in International Taxation) from the University of Melbourne and a master's degree in commerce from the University of NSW.

Paradigm's CEO and Chairman, Paul Rennie commented *"we are delighted to have Helen join our Board and her experience in the health care sector will be important as Paradigm begins to operationalise its harmonised clinical trials in the USA, Australia and*

Europe. Helen will also be able to provide guidance and oversee our international pricing strategy for Zilosul®, including on transfer pricing and multi-jurisdictional tax matters.”

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by the Paradigm Board.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com